Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jonathan N. T. Yu, MD"'
Autor:
Niamh Corduff, MBBS, FRACS, Je-Young Park, MD, Pacifico E. Calderon, MD, MBEth, MEd, Hosung Choi, MD, Mary Dingley, MBBS, FACCSM, FCPCA, Wilson W. S. Ho, MBChB, FRCSEd, Michael U. Martin, PhD, Lis S. Suseno, MD, Fang-Wen Tseng, MD, Vasanop Vachiramon, MD, Rungsima Wanitphakdeedecha, MD, MA, MSc, Jonathan N. T. Yu, MD
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 12, Iss 6, p e5892 (2024)
Background:. As long-term, regular aesthetic botulinum neurotoxin A (BoNT-A) use becomes more commonplace, it is vital to understand real-world risk factors and impact of BoNT-A immunoresistance. The first Aesthetic Council on Ethical Use of Neurotox
Externí odkaz:
https://doaj.org/article/be2c0341340d465c9548fd917449176c
Autor:
Wilson W. S. Ho, MBChB, FRCSEd, Philipp Albrecht, MD, Pacifico E. Calderon, MD, MBEth, Niamh Corduff, MBBS, FRACS, David Loh, MBBS, Michael U. Martin, PhD, Je-Young Park, MD, Lis S. Suseno, MD, Fang-Wen Tseng, MD, Vasanop Vachiramon, MD, Rungsima Wanitphakdeedecha, MD, MA, MSc, Chong-Hyun Won, MD, PhD, Jonathan N. T. Yu, MD, Mary Dingley, MBBS, FACCSM, FCPCA
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 10, Iss 6, p e4407 (2022)
Background:. Botulinum neurotoxin A (BoNT-A) injection is the most widely performed aesthetic procedure and a first-line therapeutic option for various medical conditions. The potential for BoNT-A immunoresistance and secondary nonresponse related to
Externí odkaz:
https://doaj.org/article/d3d0a0c0a8e34491a526fb886264d38c